RESUMO
INTRODUCTION: We assessed the effect of the prandial state on the pharmacokinetics, safety, and tolerability of single and multiple doses of orforglipron (LY3502970), an oral, non-peptide glucagon-like peptide 1 receptor agonist (GLP-1 RA), in two studies (A and B). METHODS: Study A and study B were phase 1, randomized, crossover studies in healthy adults aged 18-65 years and 21-70 years, respectively. Participants received single (3 mg, study A) or multiple (16 mg, study B) oral doses of orforglipron under fasted and fed conditions. Blood samples were collected pre- and postdose to assess area under the concentration-time curve (AUC), maximum observed drug concentration (Cmax), time of Cmax (tmax), and half-life (t1/2) associated with terminal rate constant. AUC and Cmax were analyzed using a linear mixed-effects model. Treatment differences were presented as ratios of geometric least squares means (GLSM). Treatment-emergent adverse events (TEAEs), adverse events of special interest, and serious adverse events were assessed. RESULTS: Study A included 12 participants (mean age 45.0 years; male 66.7%); study B included 34 participants (mean age 42.8 years; male 88.2%). GLSM AUC and Cmax were lower by 23.7% and 23.2% in study A, and 17.6% and 20.9% in study B, in the fed versus fasted states, respectively. In both studies, t1/2 and median tmax were comparable between fed and fasted states. The majority of TEAEs in both studies were gastrointestinal tract-related conditions. No serious adverse events or deaths were reported in either study. CONCLUSION: The observed pharmacokinetic differences due to the prandial state are unlikely to contribute to clinically meaningful differences in the efficacy of orforglipron. The safety profile was consistent with the known profiles of other GLP-1 RAs. Given the absence of prandial restrictions, orforglipron may emerge as a convenient oral treatment option for patients with type 2 diabetes or obesity. TRIAL REGISTRATION: ClinicalTrials.gov identifiers, NCT03929744 and NCT05110794.
RESUMO
Drug-delivery technologies for modified drug release have been in existence for decades, but their utilization has been largely limited to post-launch efforts improving therapeutic outcomes. Recently, they have gained renewed importance because the pharmaceutical industry is steadily shifting to a more integrated discovery-development approach. In discovery, modulating target engagement via drug-delivery technologies can enable crucial pharmacological studies for building well-defined criteria for molecular design. In development, earlier implementation of delivery technologies can enhance the value of drug products through reduced dosing frequency and improved tolerability and/or safety profile, thereby leading to better adherence and therapeutic effectiveness.
Assuntos
Sistemas de Liberação de Medicamentos , Desenvolvimento de Medicamentos/métodos , Descoberta de Drogas/métodos , Animais , Desenho de Fármacos , Desenvolvimento de Medicamentos/tendências , Descoberta de Drogas/tendências , Indústria Farmacêutica/métodos , Indústria Farmacêutica/tendências , Liberação Controlada de Fármacos , Humanos , Tecnologia Farmacêutica/métodos , Tecnologia Farmacêutica/tendênciasRESUMO
We describe a novel class of acidic mPGES-1 inhibitors with nanomolar enzymatic and human whole blood (HWB) potency. Rational design in conjunction with structure-based design led initially to the identification of anthranilic acid 5, an mPGES-1 inhibitor with micromolar HWB potency. Structural modifications of 5 improved HWB potency by over 1000×, reduced CYP2C9 single point inhibition, and improved rat clearance, which led to the selection of [(cyclopentyl)ethyl]benzoic acid compound 16 for clinical studies. Compound 16 showed an IC80 of 24nM for inhibition of PGE2 formation in vitro in LPS-stimulated HWB. A single oral dose resulted in plasma concentrations of 16 that exceeded its HWB IC80 in both rat (5mg/kg) and dog (3mg/kg) for over twelve hours.
Assuntos
Benzoatos/química , Benzoatos/farmacologia , Descoberta de Drogas , Microssomos/efeitos dos fármacos , Prostaglandina-E Sintases/antagonistas & inibidores , Animais , Cristalografia por Raios X , Cães , Microssomos/enzimologia , Prostaglandina-E Sintases/química , RatosRESUMO
Here we report on novel, potent 3,3-dimethyl substituted N-aryl piperidine inhibitors of microsomal prostaglandin E synthases-1(mPGES-1). Example 14 potently inhibited PGE2 synthesis in an ex vivo human whole blood (HWB) assay with an IC50 of 7nM. In addition, 14 had no activity in human COX-1 or COX-2 assays at 30µM, and failed to inhibit human mPGES-2 at 62.5µM in a microsomal prep assay. These data are consistent with selective mPGES-1-mediated reduction of PGE2. In dog, 14 had oral bioavailability (74%), clearance (3.62mL/(min*kg)) and volume of distribution (Vd,ss=1.6L/kg) values within our target ranges. For these reasons, 14 was selected for further study.
Assuntos
Piperidinas/química , Piperidinas/farmacologia , Prostaglandina-E Sintases/antagonistas & inibidores , Células A549 , Animais , Cristalografia por Raios X , Cães , Humanos , Piperidinas/farmacocinética , Ratos , Especificidade da Espécie , Relação Estrutura-AtividadeRESUMO
As part of a program aimed at the discovery of antinociceptive therapy for inflammatory conditions, a screening hit was found to inhibit microsomal prostaglandin E synthase-1 (mPGES-1) with an IC50 of 17.4 µM. Structural information was used to improve enzyme potency by over 1000-fold. Addition of an appropriate substituent alleviated time-dependent cytochrome P450 3A4 (CYP3A4) inhibition. Further structure-activity relationship (SAR) studies led to 8, which had desirable potency (IC50 = 12 nM in an ex vivo human whole blood (HWB) assay) and absorption, distribution, metabolism, and excretion (ADME) properties. Studies on the formulation of 8 identified 8·H3PO4 as suitable for clinical development. Omission of a lipophilic portion of the compound led to 26, a readily orally bioavailable inhibitor with potency in HWB comparable to celecoxib. Furthermore, 26 was selective for mPGES-1 inhibition versus other mechanisms in the prostanoid pathway. These factors led to the selection of 26 as a second clinical candidate.
Assuntos
Analgésicos/síntese química , Analgésicos/farmacologia , Inibidores de Ciclo-Oxigenase/síntese química , Inibidores de Ciclo-Oxigenase/farmacologia , Imidazóis/síntese química , Imidazóis/farmacologia , Oxirredutases Intramoleculares/antagonistas & inibidores , Microssomos/enzimologia , Animais , Anti-Inflamatórios não Esteroides/farmacologia , Disponibilidade Biológica , Celecoxib/farmacologia , Inibidores de Ciclo-Oxigenase/farmacocinética , Citocromo P-450 CYP3A , Inibidores das Enzimas do Citocromo P-450/síntese química , Inibidores das Enzimas do Citocromo P-450/farmacologia , Cães , Descoberta de Drogas , Humanos , Microssomos/efeitos dos fármacos , Modelos Moleculares , Prostaglandina-E Sintases , Ratos , Relação Estrutura-AtividadeRESUMO
Fatty acid amide hydrolase (FAAH) is an integral membrane serine hydrolase that degrades the fatty acid amide family of signaling lipids, including the endocannabinoid anandamide. Genetic or pharmacological inactivation of FAAH leads to analgesic and anti-inflammatory phenotypes in rodents without showing the undesirable side effects observed with direct cannabinoid receptor agonists, indicating that FAAH may represent an attractive therapeutic target for the treatment of inflammatory pain and other nervous system disorders. Herein, we report the discovery and characterization of a highly efficacious and selective FAAH inhibitor PF-04457845 (23). Compound 23 inhibits FAAH by a covalent, irreversible mechanism involving carbamylation of the active-site serine nucleophile of FAAH with high in vitro potency (k(inact)/K(i) and IC(50) values of 40300 M(-1) s(-1) and 7.2 nM, respectively, for human FAAH). Compound 23 has exquisite selectivity for FAAH relative to other members of the serine hydrolase superfamily as demonstrated by competitive activity-based protein profiling. Oral administration of 23 at 0.1 mg/kg results in efficacy comparable to that of naproxen at 10 mg/kg in a rat model of inflammatory pain. Compound 23 is being evaluated in human clinical trials.
RESUMO
Dogs are one of the most commonly used non-rodent species in toxicology studies and are known to have basal stomach pH ranging from 2 to 7 in the fasted state. Thus absorption and resulting plasma exposure of weakly basic compounds administered as crystalline suspensions to dogs are often variable. LY2157299 is a potent and selective transforming growth factor (TGF)-beta receptor type 1 kinase (TGF-ßRI) inhibitor that displayed variable absorption in early dog studies. This molecule is a weakly basic Biopharmaceutics Classification System (BCS)Class II compound, and depends on the rate and extent of dissolution to drive oral absorption. An artificial stomach and duodenum (ASD) dissolution model was utilized to evaluate potential effect of gastric pH on the absorption of suspension and buffered solution formulations. GastroPlus™ was also employed to predict the magnitude of gastric pH changes on LY2157299 absorption. The ASD experiments demonstrated that administration of a buffered acidic solution could improve the potential for absorption by normalizing gastric pH and enabling supersaturation in the duodenum. GastroPlus™ modeling suggested that direct modulation of gastric pH could lead to marked changes in bioavailability. Pharmacokinetic experiments were conducted in dogs to evaluate the effect of gastric pH modification on plasma exposure. The data were qualitatively consistent with the predictions.
Assuntos
Órgãos Artificiais , Duodeno/metabolismo , Suco Gástrico/metabolismo , Mucosa Gástrica/metabolismo , Concentração de Íons de Hidrogênio , Pirazóis/farmacocinética , Quinolinas/farmacocinética , Animais , Disponibilidade Biológica , Cães , Masculino , Proteínas Serina-Treonina Quinases/antagonistas & inibidores , Receptor do Fator de Crescimento Transformador beta Tipo I , Receptores de Fatores de Crescimento Transformadores beta/antagonistas & inibidores , SolubilidadeRESUMO
The endogenous cannabinoid (endocannabinoid) anandamide is principally degraded by the integral membrane enzyme fatty acid amide hydrolase (FAAH). Pharmacological blockade of FAAH has emerged as a potentially attractive strategy for augmenting endocannabinoid signaling and retaining the beneficial effects of cannabinoid receptor activation, while avoiding the undesirable side effects, such as weight gain and impairments in cognition and motor control, observed with direct cannabinoid receptor 1 agonists. Here, we report the detailed mechanistic and pharmacological characterization of N-pyridazin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide (PF-04457845), a highly efficacious and selective FAAH inhibitor. Mechanistic studies confirm that PF-04457845 is a time-dependent, covalent FAAH inhibitor that carbamylates FAAH's catalytic serine nucleophile. PF-04457845 inhibits human FAAH with high potency (k(inact)/K(i) = 40,300 M(-1)s(-1); IC(50) = 7.2 nM) and is exquisitely selective in vivo as determined by activity-based protein profiling. Oral administration of PF-04457845 produced potent antinociceptive effects in both inflammatory [complete Freund's adjuvant (CFA)] and noninflammatory (monosodium iodoacetate) pain models in rats, with a minimum effective dose of 0.1 mg/kg (CFA model). PF-04457845 displayed a long duration of action as a single oral administration at 1 mg/kg showed in vivo efficacy for 24 h with a concomitant near-complete inhibition of FAAH activity and maximal sustained elevation of anandamide in brain. Significantly, PF-04457845-treated mice at 10 mg/kg elicited no effect in motility, catalepsy, and body temperature. Based on its exceptional selectivity and in vivo efficacy, combined with long duration of action and optimal pharmacokinetic properties, PF-04457845 is a clinical candidate for the treatment of pain and other nervous system disorders.
Assuntos
Amidoidrolases/antagonistas & inibidores , Inibidores Enzimáticos/farmacologia , Inibidores Enzimáticos/uso terapêutico , Dor/tratamento farmacológico , Dor/enzimologia , Piridazinas/farmacologia , Piridazinas/uso terapêutico , Ureia/análogos & derivados , Amidoidrolases/metabolismo , Animais , Inibidores Enzimáticos/química , Humanos , Inflamação/tratamento farmacológico , Inflamação/enzimologia , Inflamação/patologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Piperidinas/química , Piperidinas/farmacologia , Piperidinas/uso terapêutico , Piridazinas/química , Ratos , Ratos Sprague-Dawley , Ureia/química , Ureia/farmacologia , Ureia/uso terapêuticoRESUMO
This work reports on the solubility of two weakly basic model compounds in media containing sodium lauryl sulfate (SLS). Results clearly show that the presence of SLS in the media (e.g. simulated gastric fluid or dissolution media) can result in an underestimation of solubility of some weak bases. We systematically study this phenomenon and provide evidence (chromatography and pXRD) for the first time that the decrease in solubility is likely due to formation of a less soluble salt/complex between the protonated form of the weak base and lauryl sulfate anion.
Assuntos
Antimaláricos/farmacocinética , Suco Gástrico/metabolismo , Excipientes Farmacêuticos/química , Dodecilsulfato de Sódio/química , Tensoativos/química , Trimetoprima/farmacocinética , Antimaláricos/análise , Antimaláricos/química , Precipitação Química , Cromatografia Líquida de Alta Pressão , Difusão , Suco Gástrico/química , Mucosa Gástrica/metabolismo , Concentração de Íons de Hidrogênio , Absorção Intestinal , Excipientes Farmacêuticos/análise , Difração de Pó , Reprodutibilidade dos Testes , Dodecilsulfato de Sódio/análise , Solubilidade , Tensoativos/análise , Trimetoprima/análise , Trimetoprima/químicaRESUMO
The design and validation of a novel high-throughput system for thermodynamic solubility determination requiring only 5 mg of sample is described. The system uses a sintered nickel filter assembly to recover excess solids from saturated solutions for rapid crystallinity assessment via powder X-ray diffraction (PXRD). Moreover, the system measures the pH of filtrates to provide a final pH value with the solubility measurement. The limit of detection for the UV-vis plate reader used on this system is approximately 0.001 mg/ml, while the practical upper limit is approximately 3 mg/mL. The solubility measurements of 60 proprietary Pfizer compounds were used to validate the nickel filter assembly against a more conventional polyvinylidenedifluoride (PVDF) filter. Additionally, a comparison was made between a subset of 10 compounds run on the automated system and a more traditional shake-flask method employing HPLC analysis. In both cases, a favorable comparison was obtained.
Assuntos
Desenho de Fármacos , Preparações Farmacêuticas/química , Autoanálise , Automação , Soluções Tampão , Química Farmacêutica/métodos , Cromatografia Líquida de Alta Pressão , Cristalização , Filtração , Concentração de Íons de Hidrogênio , Níquel/química , Pós , Padrões de Referência , Solubilidade , Espectrofotometria Ultravioleta , Termodinâmica , Difração de Raios XRESUMO
In drug development, the thermodynamically most stable form of a compound is preferred because metastable forms are prone to transform to the stable form during processing, formulation, or storage [Guillory, J.K., 1999. Generation of polymorphs, hydrates, solvates, and amorphous solids. In: Brittain, H.G. (Ed.), Polymorphism in Pharmaceutical Solids. Marcel Dekker, New York, pp. 183-226]. It is therefore important to discover and characterize the stable form as early as possible. One of the most important properties to determine is thermodynamic solubility. However, due to compound and time constraints this solubility value is usually not determined until late in discovery. This report explores the ability of the pH-metric titration method to measure intrinsic solubility of the stable form of compounds that exist in one or more polymorphic forms. One metastable form and the stable form of eight compounds were examined. Intrinsic solubility was measured via pH-metric titration. The technique was performed on a larger scale in order to monitor polymorphic form changes by powder X-ray diffraction. Shake-flask solubility and corresponding X-ray diffraction data of each form was also determined. The results of this study indicate that, in general, when starting with a metastable polymorph, the pH-metric titration method is able to achieve the solubility of the stable form by the third titration, while the traditional shake-flask solubility method is unable to consistently determine the stable form solubility.
Assuntos
Preparações Farmacêuticas/química , Potenciometria/métodos , Acetaminofen/química , Acetazolamida/química , Clorpropamida/química , Cristalografia por Raios X , Fluoroquinolonas/química , Furosemida/química , Concentração de Íons de Hidrogênio , Pirróis/química , Quinolonas/química , Solubilidade , Sulfametoxazol/química , Sulfatiazol , Sulfatiazóis/química , Termodinâmica , Titulometria/métodosRESUMO
Solubility data are used to make crucial decisions from the earliest stages of drug discovery throughout the development process, but often the decision-maker is far removed, in terms of both organization and scientific background, from the scientist who generates the data. Here we provide a reference point for consumers of solubility who are presented with increasingly sophisticated strategies to measure sooner, faster or more accurately. We discuss the fundamental forces that govern solubility, the role of physical-chemical parameters such as pH and pK(a), and the principles involved in different solubility measurements. Our ultimate goal is to enable a decision-maker, when presented with solubility data, to have in hand the tools to evaluate not just the magnitude but also the context and appropriateness of those measurements to the drug in question.
Assuntos
Química Farmacêutica , Preparações Farmacêuticas/química , Concentração de Íons de Hidrogênio , Modelos Químicos , Estrutura Molecular , Solubilidade , Tecnologia Farmacêutica , TermodinâmicaRESUMO
Solubility measurements using chemiluminescent nitrogen detection (CLND) has advantages of reduced compound requirement and increased throughput compared to UV-spectrophotometric and HPLC-based measurements. CLND with direct flow injection was evaluated for the measurement of thermodynamic solubility to support drug discovery. The limit of quantitation (LOQ), accuracy, and day-to-day reproducibility of the detector were measured. Measurements made on CLND were compared to those obtained from UV spectrophotometry and HPLC. Based on the results obtained, it was concluded that the CLND performs satisfactorily for discovery stage thermodynamic solubility measurements.
Assuntos
Química Farmacêutica/métodos , Desenho de Fármacos , Luminescência , Nitrogênio/análise , Tecnologia Farmacêutica/métodos , Calibragem , Cromatografia Líquida de Alta Pressão , Relação Dose-Resposta a Droga , Estudos de Avaliação como Assunto , Concentração de Íons de Hidrogênio , Solubilidade , Espectrofotometria Ultravioleta , Termodinâmica , Raios UltravioletaRESUMO
Micronization is a commonly used enabling technology to improve the bioavailability of compounds where absorption is dissolution rate limited. However, decreasing particle size often results in increased Van der Waals' interactions and electrostatic attraction between particles. This causes agglomeration of particles, thereby compromising the increase in surface area gained by micronization. Comicronization with excipients has been reported to offer significant advantages over neat micronization. The present work describes the comicronization of a model compound CI-1040 at a high drug load that shows an increase in the dissolution rate and bioavailability in male Wistar rats. Physicochemical characterization of the comicronized and neat micronized material is presented to help explain the in-vitro and in-vivo data.
Assuntos
Benzamidas/química , Benzamidas/farmacocinética , Celulose/química , Excipientes/química , Tecnologia Farmacêutica/métodos , Animais , Disponibilidade Biológica , Masculino , Microscopia Eletrônica de Varredura , Tamanho da Partícula , Ratos , Ratos Wistar , Solubilidade , Propriedades de Superfície , Difração de Raios XRESUMO
The flow properties of pharmaceutical powders and blends used in solid oral dosage forms are an important consideration during dosage form development. The vibratory feeder method, a flow measurement technique that quantifies avalanche flow, has been adapted for measurement of the flow properties of common pharmaceutical powders used in solid oral dosage forms. The flow properties of 17 different powders were measured with the instrument, and the results are reported as a powder flow index (PFI). The PFI trends of the powders correlate well with flow properties reported in the literature. The flow properties of the powders were also measured with a commercially available avalanche instrument, the Aero-Flow, and the results were reported as the mean time to avalanche (MTA). Since the two instruments analyze the avalanche by different algorithms, the results were compared with nonparametric statistical evaluation of ranked data, and they were found to be in excellent agreement. A recommended procedure for measurement of powder flow with the vibratory feeder is presented.
Assuntos
Tecnologia Farmacêutica/instrumentação , Pós , Tecnologia Farmacêutica/métodosRESUMO
Dissolution of Pfizer Compound PD198306, a poorly soluble compound, was studied in 25 mM pH 9 sodium phosphate solution with 0.5% SLS using the flow-through cell dissolution apparatus. Unmicronized and micronized drug powders were tested. Several methods of loading the drug powder into the flow-through dissolution cells and their impact on dissolution were investigated. The influence of flow rate of the dissolution medium on the rate and extent of dissolution were studied. PD198306 has poor wettability even in the presence of 0.5% SLS. It was found that loading the drug powder into the dissolution cell in the form of a suspension provided the best dissolution profile in terms of the rate and extent of dissolution. The flow rate of 4 ml/min resulted in good particle size discrimination.